CRISPR Therapeutics and the broader biomedical and genetics industry were operating within the medical sector, with stock performance noted against the S&P 500 on July 16, 2025.

1 report, 1 independent Updated Jul 16

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Who's involved

What this event is mainly about

CRISPR Therapeutics

Keep exploring

Part of

CRISPR Therapeutics stock performance and Zacks Rank rating were reported on July 26, 2025, within the biomedical sector. All 1 developments

The entities involved

CRISPR Therapeutics
company in Basel, Switzerland
- CRISPR Therapeutics formed a strategic partnership with Vertex Pharmaceuticals.Sat 22:51
- CRISPR Therapeutics announced that A.J. Silver will succeed Raju Prasad as CFO, following Silver's time at Ernst & Young LLP.Mon 22:45

Related events

CRISPR Therapeutics and Vertex Pharmaceuticals received FDA approval for their gene therapy Casgevy for sickle cell disease.Jun 22

Coverage

Newest first; wire copies grouped

Jul 16ZacksCRISPR Therapeutics AG (CRSP) Declines More Than Market: Some Information for Investors CRISPR Therapeutics AG (CRSP) ended the recent trading session at $52.73, demonstrating a -6.54% change from th